Modality
mRNA
MOA
BCMA ADC
Target
CFTR
Pathway
Angiogenesis
MCLPNHMelanoma
Development Pipeline
Preclinical
~Jul 2018
→ ~Oct 2019
Phase 1
~Jan 2020
→ ~Apr 2021
Phase 2
~Jul 2021
→ ~Oct 2022
Phase 3
Jan 2023
→ Apr 2029
Phase 3Current
NCT05767418
2,192 pts·Melanoma
2025-05→2027-06·Active
NCT04674355
35 pts·MCL
2023-01→2028-03·Terminated
NCT07182564
1,786 pts·MCL
2024-03→2029-04·Terminated
+1 more trial
5,868 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2027-01-119mo awayPh3 Readout· Melanoma
2027-06-271.2y awayPh3 Readout· Melanoma
2028-03-081.9y awayPh3 Readout· MCL
2029-04-173.0y awayPh3 Readout· MCL
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P3
Termina…
P3
Active
P3
Termina…
P3
Active
Catalysts
Ph3 Readout
2027-01-11 · 9mo away
Melanoma
Ph3 Readout
2027-06-27 · 1.2y away
Melanoma
Ph3 Readout
2028-03-08 · 1.9y away
MCL
Ph3 Readout
2029-04-17 · 3.0y away
MCL
ActiveTerminated|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05767418 | Phase 3 | Melanoma | Active | 2192 | Mayo |
| NCT04674355 | Phase 3 | MCL | Terminated | 35 | MRD |
| NCT07182564 | Phase 3 | MCL | Terminated | 1786 | PANSS |
| NCT04164871 | Phase 3 | Melanoma | Active | 1855 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Datoglumide | AbbVie | Approved | CFTR | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| Fixatuximab | Legend Biotech | Preclinical | CFTR | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα |